Cross-institution positioning
Jul 28, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchInhibikase Therapeutics, Inc.
Latest stored close $1.97 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/58 non-amendment material events in the last 90 days; 2 capital-related filing/events (2 equity-related, 0 debt-related); Latest classified evidence: Regulation FD disclosure. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataNet income -97.6% YoY; Free cash flow -152.8% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 77% through its reported 52-week range; +44.4% over one year.
Source: Stored historical price seriesFiled Jul 28, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BERMAN DENNIS N | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 21.9K | $0.00 | Direct | Jul 31, 2026 |
| Jul 30, 2026 | BERMAN DENNIS N | MExercise or conversion of derivative | Common Stock | 21.9K | $1.26 | Direct | Jul 31, 2026 |
| Jul 29, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | JOther transaction · derivative | Pre-Funded Warrant (Right to Buy) | 18.0M | — | Indirect | Jul 31, 2026 |
| Jul 29, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | JOther transaction | Common Stock | 18.0M | — | Indirect | Jul 31, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 8, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 26, 2026 | 8-K | 4.01, 9.01 | Auditor change; Financial statements / exhibits | — | Filing |
| Aug 11, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Aug 11, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 29, 2026 | 8-K | 3.02, 9.01 | Unregistered sale of equity securities; Financial statements / exhibits | Equity | Filing |
| Jul 23, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jul 14, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Jun 29, 2026 | 8-K | 5.02, 5.03, 5.07, 9.01 | Director or executive change; Charter or bylaw change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $0 | — |
| Ended Jun 30, 2025 | $0 | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 28, 2026 filed · 28d Initial Schedule 13G | Initial Schedule 13G | 7.8M | 12.00% | $2.03 | $2.31 | $1.97 |
| BlackRock CIK0002012383 | Dec 31, 2024 quarter end Feb 7, 2025 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 335.5K | $1.97 |
Compare IKT with other securities showing similar institutional activity or recent accumulation across several tracked institutions.